Ignite Creation Date:
2024-05-06 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 12:51 PM
Study NCT ID:
NCT03624543
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-02-12
First Post:
2018-08-01
Brief Title:
CFI-400945 in Patients With AdvancedMetastatic Breast Cancer
Sponsor:
Canadian Cancer Trials Group
Organization:
Canadian Cancer Trials Group
Study Overview
Official Title:
A Phase II Study of CFI-400945 in Patients With AdvancedMetastatic Breast Cancer
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The standard or usual treatment for this disease is to undergo chemotherapy to slow the spread of the disease and relieve some symptoms of cancer Patients will have already had at least one chemotherapy treatment for their disease at this stage
Detailed Description:
CFI-400945 is a new type of drug for breast cancer Laboratory tests show that it works by blocking a specific protein called Polo-like Kinase 4 PLK4 that is involved in cancer cell growth CFI-400945 may slow down the growth of cancer cells or may cause cancer cells to die This drug has been shown to shrink tumours in animals and has been studied in some patients and appears well tolerated with little side effects CFI-400945 seems promising but it is not clear if it can offer better results than standard therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None